Q&A: Zeposia may be efficacious oral therapy for UC

Zeposia may be an efficacious new oral therapy option with a favorable risk-benefit profile for patients with ulcerative colitis.Bristol-Myers Squibb recently announced results from the pivotal phase 3 trial, True North, which assessed oral Zeposia (ozanimod, Bristol-Meyers Squibb) as an induction and maintenance therapy for adult patients with moderate to severe UC, according to a press releaseTruth North met the primary endpoints at week 52 and demonstrated statistically significant results for induction and maintenance in adults with UC. Healio Gastroenterology spoke with William J.Read More

Share on facebook
Share on twitter
Share on linkedin